A double-blind, randomized, controlled trial in Australia showed that oral nicotinamide (vitamin B3) was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients. The trial randomly assigned 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months. At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% in the nicotinamide group than in the placebo group. Similar differences were found between the two groups with respect to new basal-cell carcinomas (20% lower rate with nicotinamide), new squamous-cell carcinomas (30% lower rate) and the number of actinic keratoses (11-20% lower). No noteworthy between-group differences were found with respect to the number or types of adverse events during the 12-month intervention period, and there was no evidence of benefit after nicotinamide was discontinued. Source: http://www.nejm.org/
一项澳大利亚的双盲，随机对照试验发现，口服烟酰胺（维生素B3）安全，有效地减少高危患者新的非黑色素瘤皮肤癌和光化性角化病的发生率。该试验随机分配386名在过去5年已有至少两个非黑色素瘤皮肤癌的参与者，每日两次服用500毫克烟酰胺或安慰剂治疗12个月。在12个月时，烟酰胺组新的非黑色素瘤皮肤癌发生率比安慰剂组低23％。发现两组之间的其它差异亦类似，无论对于新基底细胞癌（烟酰胺组低20％），新的鳞状细胞癌（低30％）或光化性角化病的数量（低11-20％）。在12个月的干预期间不良反应的数量或类型没有值得注意的组间差异，且无任何证据表明停用烟酰胺后仍有效。来源：http://www.nejm.org/
This website uses cookies.